Evidence map›Paper›PMID 28717038›Full record

ArticleAntimicrobial agents and chemotherapy2017

A Human Biofilm-Disrupting Monoclonal Antibody Potentiates Antibiotic Efficacy in Rodent Models of both Staphylococcus aureus and Acinetobacter baumannii Infections.

Yan Q Xiong, Angeles Estellés, L Li, W Abdelhady, R Gonzales, Arnold S Bayer, Edgar Tenorio, Anton Leighton, Stefan Ryser, Lawrence M Kauvar

2 registry-linked trialsOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04763759 phase1completednot on this mapstarted 2021, after this paper: background citation

A Phase 1, Blinded, Single Ascending Dose Study to Evaluate Safety, Pharmacokinetics, and Activity of TRL1068 in Subjects With Prosthetic Joint Infection of the Knee or Hip, Undergoing Primary Two Stage Exchange Arthroplasty

TypeinterventionalSponsorTrellis Bioscience LLCRan2021 to 2024Enrolled15ConditionsProsthetic Joint InfectionArmsTRL1068, a human monoclonal antibody
NCT05355207 phase1unknown statusnot on this mapstarted 2024, after this paper: background citation

Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of TRL1068 in Subjects With Acute Exacerbation of Chronic Rhinosinusitis

TypeinterventionalSponsorTrellis Bioscience LLCRan2024 to 2025Enrolled12ConditionsChronic Rhinosinusitis With Nasal PolypsArmsTRL1068
3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 58 citations in OpenAlex.

  1. Trial
  2. Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026
    Review
  3. Review
  4. Conserved CD4Nature microbiology · 2026
    Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Yan Q XiongLos Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, USA.
Angeles EstellésTrellis Bioscience, LLC, Menlo Park, California, USA.
L LiLos Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, USA.
W AbdelhadyLos Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, USA.
R GonzalesLos Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, USA.
Arnold S BayerLos Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, USA.
Edgar TenorioTrellis Bioscience, LLC, Menlo Park, California, USA.
Anton LeightonTrellis Bioscience, LLC, Menlo Park, California, USA.
Stefan RyserTrellis Bioscience, LLC, Menlo Park, California, USA.
Lawrence M KauvarTrellis Bioscience, LLC, Menlo Park, California, USA lkauvar@trellisbio.com.
Trellis Bioscience (United States) · USThe Lundquist Institute · USHarbor–UCLA Medical Center · USMenlo School · US

Funding

Therapeutic Antibodies for Biofilm InfectionsSB1AI120425 · NIAID · TRELLIS BIOSCIENCE, INC. · PI KAUVAR, LAWRENCE MICHAEL · 2017 to 2019
$3.0M
Therapeutic Antibodies for Biofilm InfectionsR44AI120425 · NIAID · TRELLIS BIOSCIENCE, INC. · PI KAUVAR, LAWRENCE MICHAEL · 2016 to 2016
$1000k
NIAID NIH HHS R44 AI120425NIAID NIH HHS SB1 AI120425
6 · The paper itself

Abstract

Many serious bacterial infections are antibiotic refractory due to biofilm formation. A key structural component of biofilm is extracellular DNA, which is stabilized by bacterial proteins, including those from the DNABII family. TRL1068 is a high-affinity human monoclonal antibody against a DNABII epitope conserved across both Gram-positive and Gram-negative bacterial species. In the present study, the efficacy of TRL1068 for the disruption of biofilm was demonstrated

Indexed as

Acinetobacter baumanniiAcinetobacter InfectionsAnimalsAnti-Bacterial AgentsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAortic ValveBiofilmsDrug Therapy, CombinationEndocarditisEpitopesFemaleHumansImipenemMethicillin-Resistant Staphylococcus aureusMiceAnti-Bacterial AgentsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedEpitopesImipenemTRL1068VancomycinAcinetobacterbiofilmsinfective endocarditismonoclonal antibodyMRSAskin and soft tissue infection

Identifiers

PMID28717038
PMCPMC5610488
OpenAlexW2736205799

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.